At Danderyd Hospital, all forms of neuroinflammatory diseases affecting both the peripheral and central nervous system are treated. In our projects, we collaborate both nationally and internationally.

The main focus area of the Neuroinflammatory research group is clinical research in Multiple Sclerosis (MS). The group has performed extensive research regarding safety and efficacy of rituximab in MS, among which has been the coordination of the first randomized controlled phase 3 trials of Rituximab in MS - the RIFUND-MS trial and its follow-up trial RIDOSE-MS. These trials have been instrumental in the documentation of Rituximab in MS and have had a strong impact of its use internationally.

At Danderyd Hospital, all forms of neuroinflammatory diseases affecting both the peripheral and central nervous system are treated. In our projects, we collaborate both nationally and internationally.